Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Apogee Therapeutics, Inc.NASDAQ: APGE
Net Receivables · Q2 FY2026 · quarter ended Jun 2026
Net receivables remains negative
Q2 FY2026 net receivables was $0, compared with $4.14M a year earlier.
Context
- Net receivables amounted to 0.0% of total assets at the end of Q2 FY2026, down 0.6 pp from a year earlier.
- Net receivables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 5.96M USD
- Year-over-year change
- +26.9%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.96M | +26.9% |
| FY2024 | 2024-12-31 | 4.7M | +286.9% |
| FY2023 | 2023-12-31 | 1.21M | — |
| FY2022 | 2022-12-31 | 0 | — |
Net Receivables vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -100.0% is the lowest of 8, against a peer median of +22.4%.
- Net receivables amounts to 0.0% of total assets for APGE, versus a peer median of 6.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥253.1M CNY | +155.5% | +60.3% | 6.4% |
| Sep 2026 | $218.9M USD | +8.1% | +77.8% | 13.0% | |
| Mar 2026 | $121M USD | +22.4% | +57.8% | 9.3% | |
| Jun 2026 | $72.99M USD | -26.5% | +29.8% | 6.8% | |
| Mar 2026 | $62.46M USD | +18.5% | +31.2% | 9.7% | |
| Sep 2026 | $1.17M USD | +44.0% | +11.6% | 0.1% | |
| Sep 2026 | $666K USD | +29.3% | +31.4% | 0.1% | |
| Jun 2026 | $0 USD | -100.0% | — | 0.0% | |
| Jun 2026 | $0 USD | — | — | 0.0% | |
IRONDisc Medicine, Inc. | Sep 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding APGE) | — | +22.4% | +31.4% | 6.4% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.